V.I.
After relapsed B-ALL returned despite a stem cell transplant and several therapies, V.I. reached MRD-negative status following CD19 CAR-T in China.
Why the Family Contacted CancerFax
The family faced a wall of difficult, technical questions at the worst possible time. They did not know where CAR-T cell therapy was offered for a case like V.I.'s, whether he was still eligible after a transplant, or how a family from Russia could even begin to arrange treatment in another country. This is where careful navigation mattered.
Not every hospital offering CAR-T has the programme depth needed for a heavily pre-treated, post-transplant patient. Identifying the right centre required specialist knowledge.
Eligibility for CAR-T is strict, especially after a transplant and multiple therapies. Understanding whether re-evaluation could confirm suitability needed expert input.
Medical records, translation, hospital communication, visas, and travel all had to be coordinated, in a second language, under time pressure.
"We had been told there was nothing more to try at home. We needed to know if any real option was still left for our son."β V.I.'s father
How CancerFax Helped
CancerFax worked with the family to turn a complex, multi-year medical history into a clear case that a specialist centre could review quickly, then helped them reach and communicate with a hospital experienced in CAR-T cell therapy.
V.I.'s extensive records, including his transplant history, relapse events, prior therapies, and immunophenotyping, were compiled and structured for specialist review.
CancerFax identified Lu Daopei Hospital in Beijing, a centre with significant experience in CAR-T cell therapy for relapsed and refractory leukemia.
Clinical documents were translated and communication between the family and the hospital team was managed throughout evaluation and treatment.
Visa guidance, accommodation, and on-the-ground coordination were arranged so the family could focus on V.I. rather than logistics.
V.I.'s Treatment Journey
Key steps from diagnosis to treatment and beyond.
In early 2022, V.I. was diagnosed with B-cell acute lymphoblastic leukemia in Russia. The disease did not respond adequately to early induction chemotherapy, and his case was classified as high-risk.
He received high-risk chemotherapy blocks and, in July 2022, an allogeneic haploidentical stem cell transplant from his father. This is among the most intensive treatments available for high-risk leukemia.
The leukemia relapsed more than once, including outside the bone marrow and later within it. Donor lymphocyte infusions, daratumumab, nelarabine, azacitidine, and a venetoclax-based regimen were tried. By mid-2023 the disease had become refractory to these approaches.
With local curative options largely exhausted, the family approached CancerFax. His full medical history was organised and prepared for specialist review, and Lu Daopei Hospital in Beijing was identified as a centre experienced in CAR-T cell therapy for relapsed leukemia.
At Lu Daopei Hospital, the team carried out a detailed re-evaluation to confirm the current disease status and to assess whether V.I. was a suitable candidate for CD19 CAR-T cell therapy.
Following evaluation, V.I. received CD19 CAR-T cell therapy. He tolerated the treatment well, without the severe complications that can sometimes accompany cellular therapy.
Testing after the CAR-T infusion showed no measurable residual disease, an MRD-negative result. For a patient whose leukemia had repeatedly resisted treatment, this was a meaningful and hopeful response, now followed by ongoing monitoring.
Every patient's treatment plan is individual. The pathway above describes this specific case β not a blueprint for others. Suitability for each treatment is determined by the treating clinical team based on each patient's individual clinical situation.
Where V.I. Is Today
Following CD19 CAR-T cell therapy at Lu Daopei Hospital, testing showed that V.I. had reached an MRD-negative status, meaning no leukemia could be measured by sensitive testing after the infusion. The treatment was tolerated well.
A response like this is significant, but it is not the end of the road. CAR-T responses require careful, ongoing monitoring, and V.I. remains under follow-up care. For his family, after years of relapse, reaching this point was a result they had been hoping for.
β"For the first time in a long while, we had a result that gave us hope. We are grateful for the support that helped us get here."ββ V.I.'s family
What Other Families Can Learn
V.I.'s journey offers a few practical lessons for families facing relapsed or refractory leukemia.
Being told local curative options are exhausted does not always mean every option is exhausted. Specialist review can reveal advanced therapies available elsewhere.
Advanced therapies such as CAR-T have strict eligibility criteria. Current marrow, antigen, and disease-status testing is essential before committing to a centre.
Exploring advanced options while the patient is still well enough to travel and undergo treatment can make the difference in what is possible.
Records, translation, hospital communication, and travel can be overwhelming for a family. Coordinated support removes many of these barriers.
Related on CancerFax
Frequently Asked Questions
This patient story reflects an individual treatment journey. Outcomes vary from patient to patient. The information on this page should not be taken as medical advice or a guarantee of similar results. Treatment suitability depends on diagnosis, disease status, prior therapy, molecular findings, overall health, and specialist medical evaluation. Names and identifying details may be modified to protect patient privacy. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.
Need Help Understanding the Next Step?
If you or a loved one is facing a complex cancer diagnosis, relapse, or limited treatment options, CancerFax can help you organise the case, explore relevant hospitals and doctors, and understand whether advanced treatment or clinical trial pathways may be appropriate.
Β© CancerFax Β· Patient navigation and coordination platform. CancerFax is not a medical institution and does not provide medical treatment. All clinical care is provided by independent licensed physicians and hospitals. Patient names and identifying details are modified or anonymised where required to protect privacy. Story shared with documented family consent.